MRC1 and prostate carcinoma: We also assessed the burden of Class I epitopes predicted to be processed via the proteasome, transported through TAP, and presented on the cell surface (see “Methods”), with a median 771 such epitopes per patient (ranging from 366 for prostate cancer and 2536.5 for MMR-deficient cancers).